Want to see MBX full AI Analyst Report?
MBX Stock Chart & Stats
$66.76
-$0.70(-1.13%)
At close: 4:00 PM EDT
$66.76
-$0.70(-1.13%)
Day’s Range― - ―
52-Week Range$12.94 - $72.64
Previous Close$60.9
Volume304.26K
Average Volume (3M)479.88K
Market Cap
$2.63B
Enterprise Value$2.22B
Total Cash (Recent Filing)$418.58M
Total Debt (Recent Filing)$3.34M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 05, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding48,160,095
10 Day Avg. Volume490,142
30 Day Avg. Volume479,879
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.90K
Enterprise Value/Ebitda-20.56
Forecast
1Y Price Target
$99.29Price Target Upside48.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Financial FlexibilityVery low debt relative to equity gives MBX financial flexibility while it funds clinical development. The expanded asset base indicates substantial capital has been secured for research and development, reducing leverage-related pressure over the next several quarters.
Pivotal Phase 3 Program InitiatedStarting a registrational Phase 3 study is a meaningful development milestone that advances canvuparatide toward potential commercialization. The global trial, commercial-use device, and defined efficacy and safety endpoints create a clearer path to testing product viability.
Clinical And Pipeline Progress Backed By CashSustained clinical data and multiple obesity development candidates broaden MBX’s potential product base beyond one program. The reported cash position and expected runway into 2029 provide time to advance these assets without immediate financing pressure.
Bears Say
No Revenue And Widening LossesMBX has not yet established commercial revenue, while net and operating losses continue to widen. This indicates the company remains dependent on successful clinical development before operating leverage can emerge, leaving earnings power uncertain over the next several quarters.
Sustained Cash Burn Requires FinancingPersistent negative operating and free cash flow means MBX is consuming substantial cash to fund its activities rather than self-financing operations. Even with a strong current balance sheet, continued burn can reduce financial flexibility and increase future funding needs.
Senior Leadership TransitionThe simultaneous CEO transition and appointment of an interim CFO create a significant change in senior leadership during an important clinical-development period. Although the company described continuity measures, the refreshed team must execute pivotal trials and pipeline plans through a transition.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $12.94 and its highest was $72.64 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $2.63B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 26 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.633 by -$0.147.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.83.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 48,160,095 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.633. Following the earnings report the stock price went down -0.548%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.29 (48.72% Upside)
$99.29 (48.72% Upside)
Blogger Sentiment
Neutral
MBX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 108.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
235.75%
12-Months-Change
Fundamentals
Return on Equity
-26.01%
Trailing 12-Months
Asset Growth
88.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$99.29
▲(48.72% Upside)
Technical Analysis
Ownership Overview
25.68% Insiders
15.55% Mutual Funds
10.15% Other Institutional Investors
39.10% Public Companies and
Individual Investors